300791 Stock Overview
Sirio Pharma Co., Ltd. operates as a contract manufacturer for dietary supplement industry worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 4/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 2/6 |
Sirio Pharma Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥39.07 |
| 52 Week High | CN¥39.69 |
| 52 Week Low | CN¥24.24 |
| Beta | 0.77 |
| 1 Month Change | 10.84% |
| 3 Month Change | 25.43% |
| 1 Year Change | 9.87% |
| 3 Year Change | -31.97% |
| 5 Year Change | n/a |
| Change since IPO | 51.51% |
Recent News & Updates
Recent updates
Shareholder Returns
| 300791 | CN Personal Products | CN Market | |
|---|---|---|---|
| 7D | 11.7% | 6.1% | 1.6% |
| 1Y | 9.9% | -23.0% | -15.1% |
Return vs Industry: 300791 exceeded the CN Personal Products industry which returned -23% over the past year.
Return vs Market: 300791 exceeded the CN Market which returned -15.1% over the past year.
Price Volatility
| 300791 volatility | |
|---|---|
| 300791 Average Weekly Movement | 6.1% |
| Personal Products Industry Average Movement | 6.2% |
| Market Average Movement | 8.8% |
| 10% most volatile stocks in CN Market | 12.6% |
| 10% least volatile stocks in CN Market | 5.3% |
Stable Share Price: 300791's share price has been volatile over the past 3 months.
Volatility Over Time: 300791's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1993 | 2,193 | Peiqing Li | www.siriopharma.com |
Sirio Pharma Co., Ltd. operates as a contract manufacturer for dietary supplement industry worldwide. The company develops and manufactures a range of softgel dietary supplements; vegetarian softgel; nutraceutical gummies; probiotic products; tablet and powder products; capsules; and functional beverages. It also offers a range of services, including primary and final packaging.
Sirio Pharma Co., Ltd. Fundamentals Summary
| 300791 fundamental statistics | |
|---|---|
| Market cap | CN¥7.09b |
| Earnings (TTM) | CN¥221.26m |
| Revenue (TTM) | CN¥3.22b |
31.5x
P/E Ratio2.2x
P/S RatioIs 300791 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 300791 income statement (TTM) | |
|---|---|
| Revenue | CN¥3.22b |
| Cost of Revenue | CN¥2.25b |
| Gross Profit | CN¥969.27m |
| Other Expenses | CN¥748.01m |
| Earnings | CN¥221.26m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.22 |
| Gross Margin | 30.08% |
| Net Profit Margin | 6.87% |
| Debt/Equity Ratio | 33.2% |
How did 300791 perform over the long term?
See historical performance and comparison